Adicet Bio Inc
ACET
Get informed when a big investor buys or sells
+ FollowMarket Cap$85.82M
Close$
$3.51
61.6% downside
Current Fair Value
61.6% downsideOvervalued by 61.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $85.82 Million |
|---|---|
| Enterprise Value | $65.54 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.95 |
| Beta | 1.59 |
| Outstanding Shares | 10,745,553 |
Return
| Return on Equity | -82.38% |
|---|---|
| Return on Assets | -66.80% |
| Return on Invested Capital | -81.01% |
Valuation & Multiples
| P/E Ratio | -0.8 |
|---|---|
| PEG | 2.54 |
| Price to Sales | - |
| Price to Book Ratio | 0.83 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.62 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.69
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.56
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.9589▲ 395.89% |
|---|---|
| Total Calls | 10,710▼ 79.75% |
| Total Puts | 42,400▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 56.86%▼ 2.24% |
|---|---|
| Total Invested | $52.79M▲ 22.05% |
| Investors Holding | 59▲ 10.00% |
ESG Score
No data
About Adicet Bio, Inc.
152 employees
CEO: Mr. Chen Schor BA, CPA, M.B.A. Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell recepto...